First RSV vaccine for pregnant women gains FDA approval

Image credit: camylla93 via Unsplash

The U.S. Food and Drug Administration (FDA) has approved the first-ever vaccine against Respiratory Syncytial Virus (RSV) for pregnant women. This groundbreaking approval aims to protect both pregnant women and their newborns from the potentially severe respiratory infections caused by RSV. In a recent study reviewed by the FDA, the vaccine was 81.8% effective in preventing severe respiratory illness among pregnant women. With this vaccine, the medical community hopes to significantly reduce RSV-related hospitalizations and complications in the most vulnerable population.

Source

Park, Alice. “FDA Approves First RSV Vaccine for Pregnant Women.” Time, Time, 21 Aug. 2023, time.com/6306970/emabrgoed-fda-approves-first-rsv-vaccine-for-pregnant-women/.